Commission File Number 1-10827
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
________________
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended December 27, 1997
PHARMACEUTICAL RESOURCES, INC.
(Exact name of registrant as specified in its charter)
NEW JERSEY 22-3122182
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification Number)
ONE RAM RIDGE ROAD, SPRING VALLEY, NEW YORK 10977
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (914) 425-7100
Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding twelve months (or for such shorter period that
the registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days. Yes X No_______
------
18,897,629
Number of shares of Common Stock outstanding as of February 4, 1998.
This is page 1 of 15 pages. The exhibit index is on page 14.
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
PHARMACEUTICAL RESOURCES, INC.
CONSOLIDATED BALANCE SHEETS
(In Thousands, Except Share Data)
DECEMBER 27, SEPTEMBER 30,
ASSETS 1997 1997
------ ------------- --------------
(Unaudited) (Audited)
Current assets:
Cash and cash equivalents $ 52 $ 181
Accounts receivable, net of allowances of
$5,125 and $5,109 7,968 11,414
Inventories 16,450 13,239
Prepaid expenses and other current assets 3,074 3,321
-------- --------
Total current assets 27,544 28,155
Property, plant and equipment, at cost less
accumulated depreciation and amortization 27,422 27,832
Deferred charges and other assets 2,702 2,102
Non-current deferred tax benefit, net 14,608 14,608
-------- --------
Total assets $ 72,276 $ 72,697
======== ========
LIABILITIES AND SHAREHOLDERS' EQUITY
------------------------------------
Current liabilities:
Current portion of long-term debt $ 215 $ 218
Short-term debt 6,915 3,947
Accounts payable 4,270 5,120
Accrued salaries and employee benefits 1,420 1,755
Accrued expenses and other current liabilities 1,115 1,156
-------- --------
Total current liabilities 13,935 12,196
Long-term debt, less current portion 2,592 2,651
Accrued pension liability 582 582
Shareholders' equity:
Common Stock, par value $.01 per share; authorized 60,000,000 shares;
issued and outstanding 18,881,441 and 18,874,216 shares 189 189
Additional paid in capital 67,531 67,520
Accumulated deficit (12,522) (10,410)
Additional minimum liability related to defined benefit pension plan (31) (31)
-- --
Total shareholders' equity 55,167 57,268
-------- --------
Total liabilities and shareholders' equity $ 72,276 $ 72,697
======== ========
The accompanying notes are an integral part of these statements.
--2--
PHARMACEUTICAL RESOURCES, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND ACCUMULATED DEFICIT
(In Thousands, Except Per Share Amounts)
(Unaudited)
THREE MONTHS ENDED
----------------------------
DECEMBER 27, DECEMBER 28,
1997 1996
------------- -------------
Net sales $ 12,134 $12,470
Cost of goods sold
10,630 11,238
Gross margin -------- -------
1,504 1,232
Operating expenses:
Research and development 908 704
Selling, general and administrative 2,588 3,124
-------- -------
Total operating expenses 3,496 3,828
-------- -------
Operating loss (1,992) (2,596)
Other income 75 109
Interest expense (195) (82)
--- --
Loss before provision for income taxes (2,112) (2,569)
Provision for income taxes - 410
-------- -------
NET LOSS (2,112) (2,979)
Accumulated deficit, beginning of period (10,410) (1,509)
------ -----
Accumulated deficit, end of period $(12,522) $(4,488)
====== =====
(1) BASIC AND DILUTED NET LOSS PER SHARE OF COMMON STOCK $(.11) $(.16)
=== ===
(1) Weighted average number of common and
common equivalent shares outstanding 18,878 18,664
======== =======
(1) There was no effect of dilutive options in the three-month periods ended
December 27, 1997 and December 28, 1996.
The accompanying notes are an integral part of these statements.
--3--
PHARMACEUTICAL RESOURCES, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In Thousands)
(Unaudited)
THREE MONTHS ENDED
----------------------------
DECEMBER 27, DECEMBER 28,
1997 1996
------------- -------------
Cash flows from operating activities:
Net loss $(2,112) $(2,979)
Adjustments to reconcile net loss to net
cash used in operating activities:
Joint venture research and development - 148
Depreciation and amortization 654 686
Allowances against accounts receivable (16) (831)
Write-off of inventories 293 333
Gain on sale of marketable securities - (93)
Loss on sale of fixed assets 2 3
Changes in assets and liabilities:
Decrease in accounts receivable 3,462 641
Decrease (increase) in inventories (3,504) 756
Decrease (increase) in prepaid expenses and other assets (350) 2,862
Decrease in accounts payable (850) (1,137)
Decrease in accrued expenses and other liabilities (376) ( 726)
------- -------
Net cash used in operating activities (2,797) (337)
Cash flows from investing activities:
Capital expenditures (285) (269)
Proceeds from sale of fixed assets 36 78
Proceeds from sale of marketable securities - 135
------- -------
Net cash used in investing activities (249) (56)
Cash flows from financing activities:
Proceeds from issuance of Common Stock 11 14
Net proceeds from revolving credit line and proceeds
from issuance of other debt 2,968 3,624
Principal payments under long-term debt and other borrowings (62) (3,544)
Net cash provided by financing activities 2,917 94
Net decrease in cash and cash equivalents (129) (299)
Cash and cash equivalents at beginning of period 181 $ 299
------- -------
Cash and cash equivalents at end of period $ 52 -
======= =======
The accompanying notes are an integral part of these statements.
--4--
PHARMACEUTICAL RESOURCES, INC.
NOTES TO FINANCIAL STATEMENTS
DECEMBER 27, 1997
(UNAUDITED)
Pharmaceutical Resources, Inc. (the "Company" or "PRI") operates in one
business segment, the manufacture and distribution of generic pharmaceuticals.
Marketed products are principally in solid oral dosage form (tablet, caplet and
capsule), with one product in the semi-solid form of a cream and one product in
the form of a transdermal patch.
BASIS OF PREPARATION:
The accompanying financial statements at December 27, 1997 and for the three-
month periods ended December 27, 1997 and December 28, 1996 are unaudited;
however, in the opinion of management of PRI, such statements include all
adjustments (consisting of normal recurring accruals) necessary to a fair
statement of the information presented therein. The balance sheet at September
30, 1997 was derived from the audited financial statements at such date.
Pursuant to accounting requirements of the Securities and Exchange Commission
applicable to quarterly reports on Form 10-Q, the accompanying financial
statements and these notes do not include all disclosures required by generally
accepted accounting principles for audited financial statements. Accordingly,
these statements should be read in conjunction with PRI's most recent annual
financial statements.
Results of operations for interim periods are not necessarily indicative of
those to be achieved for full fiscal years. Certain items on the consolidated
financial statements for the prior years have been reclassified to conform to
the current year financial statement presentation.
ACQUISITION OF JOINT VENTURE:
In August 1997, the Company acquired from Clal Pharmaceutical Industries Ltd.
("Clal") its 51% ownership interest in their research and development joint
venture in which PRI previously had owned 49%. The Company and Clal had formed
the joint venture, located in Israel and organized under the laws of the State
of Israel, to develop, manufacture and distribute generic pharmaceutical
products worldwide. The joint venture was renamed Israel Pharmaceutical
Resources L.P. ("IPR"). The Company, through one of its subsidiaries, acquired
Clal's ownership interest for $447,000 in cash obtained from the sale of its
holdings in Fine-Tech Ltd. ("Fine-Tech"), an Israeli pharmaceutical research and
development company in which Clal had a significant ownership interest, and a
non-recourse secured promissory note for $1,500,000 bearing interest at 7%. The
note is payable in eight equal installments starting in July 1999, with the
remaining seven payments due each January and July through and including January
2003. The Company has the unconditional option to prepay the note for $600,000
by August 12, 1998. The Company is obligated to invest not less than $1,500,000
each year in IPR until the note is repaid. PRI may relocate part of IPR's
operations to the United States. In addition, the Company and Clal agreed to
modify certain terms of Clal's investment in the Company, including the
surrender by Clal of warrants to purchase approximately 2,005,000 shares of
Common Stock of the Company in exchange for the issuance to Clal of 186,000
shares of the Company's Common Stock for nominal consideration. At December 27,
1997 Clal owned approximately 12% of PRI's outstanding Common Stock.
DISTRIBUTION AGREEMENTS:
In April 1997, Par Pharmaceutical, Inc. ("Par"), the Company's operating
subsidiary, entered into a Manufacturing and Supply Agreement (the "Supply
Agreement") with BASF Corporation ("BASF"), a manufacturer of pharmaceutical
products. Under the Supply Agreement, Par agreed to purchase certain minimum
quantities of certain products manufactured by BASF at one of its facilities,
and phase out Par's manufacturing of those products. BASF agreed to discontinue
its direct sale of those products. The agreement has an initial term of three
years (subject to earlier termination upon the occurrence of certain events as
provided therein) and thereafter renews automatically for successive two-year
periods to December 31, 2005, if Par has met certain purchase thresholds. In
the event that Par's purchases do not equal or exceed the thresholds, BASF may
elect to terminate the Supply Agreement effective one year later. The Company
began selling drugs manufactured by BASF and BASF transferred to Par the
marketing and sales of certain products covered by the Supply Agreement in June
1997 and the agreement became fully implemented in August 1997.
--5--
PHARMACEUTICAL RESOURCES, INC.
NOTES TO FINANCIAL STATEMENTS--CONTINUED
DECEMBER 27, 1997
(UNAUDITED)
The Company has a distribution agreement with Sano Corporation ("Sano") which
gives Par the right to exclusively distribute three of Sano's generic products
in the United States. Sano develops transdermal delivery systems utilizing a
patch that incorporates the appropriate drug dosage into an adhesive that
attaches the patch to the skin. The Company amended its 1994 distribution
agreement in July 1997 ceding its distribution rights to three products for
which submissions then had not yet been filed with the U.S. Food and Drug
Administration ("FDA"), while retaining exclusive United States distribution
rights to three products, a nicotine transdermal patch and two nitroglycerin
transdermal patches. In addition, PRI released distribution rights outside the
United States for the retained products. In return for relinquishing the rights
described above, PRI received $1,950,000 in cash in July 1997 and an interest
bearing promissory note for $1,950,000 which will be due in September 1998.
PRI has also retained the rights to recover up to $1,500,000 of certain of its
prior payments to Sano from the gross profits earned on sales of two of the
retained products. The Company intends to purchase manufactured products from
Sano, when approved by the FDA, at cost and share in the gross profits from the
sale.
To date, Sano received FDA approval for its nicotine patch in October 1997
and awaits approval on two Abbreviated New Drug Applications ("ANDAs") for its
nitroglycerin patches, all of which are covered under the agreement. The
Company began selling the nicotine patch in January 1998.
SHORT-TERM DEBT:
In December 1996, Par entered into a Loan and Security Agreement (the "Loan
Agreement") with General Electric Capital Corporation ("GECC") which provided
Par with a three-year revolving line of credit. Pursuant to the Loan Agreement,
as amended, Par is permitted to borrow up to the lesser of (i) the borrowing
base established under the Loan Agreement or (ii) $20,000,000. The borrowing
base is limited to 85% of eligible accounts receivable plus 50% of eligible
inventory of Par, each as determined from time to time by GECC. The interest
rate charge on the line of credit is based upon a per annum rate of 3.50% above
the 30-day commercial paper rate for high-grade unsecured notes adjusted
monthly. The line of credit with GECC is secured by the assets of Par and PRI
other than real property and is guaranteed by PRI. In connection with such
facility, Par, PRI, and their affiliates have established a cash management
system pursuant to which all cash and cash equivalents received by any of such
entities are deposited into a lockbox account over which GECC has sole operating
control and which are applied on a daily basis to reduce amounts outstanding
under the line of credit. The revolving credit facility is subject to covenants
based on various financial benchmarks. In fiscal year 1997, GECC waived events
of default on three occasions unrelated to the repayment of debt under the Loan
Agreement. As of December 27, 1997, the borrowing base was approximately
$8,600,000 and $6,915,000 was outstanding under the line of credit. Any
significant reduction in the borrowing base from current levels will adversely
affect the Company's liquidity.
INCOME TAXES:
Based on the Company's recent performance and the uncertainty of the generic
business in which it operates, management believes that future operating income
might not be sufficient to recognize fully the net operating loss carryforwards
of the Company. Therefore, the Company did not recognize a benefit for its
operating losses in either of the three-month periods ended December 27, 1997 or
December 28, 1996. If the Company is unable to generate sufficient taxable
income in the future, increases in the valuation allowance will be required
through a charge to expense. The Company incurred income tax expense of
$410,000 in the first quarter of fiscal 1997 due to interest relating to a
settlement with the Internal Revenue Service in fiscal 1995 for the disallowance
of the Company's tax credit in prior periods with respect to certain research
and development credits.
--6--
PHARMACEUTICAL RESOURCES, INC.
NOTES TO FINANCIAL STATEMENTS--CONTINUED
DECEMBER 27, 1997
(UNAUDITED)
EARNINGS PER SHARE:
In February 1997, the Financial Accounting Standards Board issued Statement
of Financial Accounting Standards ("SFAS") No. 128, "Earnings Per Share" ("SFAS
128"), which is effective for financial statements for periods ending after
December 15, 1997, and requires replacement of primary and fully diluted
earnings per share with basic and diluted earnings per share including
retroactive restatement of all prior earnings per share data. Under SFAS 128,
the dilutive effect of stock options is excluded from the calculation of basic
earnings per share but included in diluted earnings per share. The Company has
adopted the new accounting standard during the quarter ended December 27, 1997
and, accordingly, has presented or restated all earnings per share data to
conform to the requirements of SFAS 128.
Outstanding options and warrants of 1,996,250 for the current three-month
period and 4,153,557 for the corresponding period of the prior year were not
included in the computation of diluted earnings per share because the exercise
prices were greater than the average market price of the Common Stock in the
respective periods. In addition, incremental shares of 1,873 from assumed
conversions in prior years calculation were excluded from diluted earnings per
share because they were antidilutive.
COMMITMENTS, CONTINGENCIES AND OTHER MATTERS:
Retirement Plans:
The Company has a defined contribution, social security integrated Retirement
Plan providing retirement benefits to eligible employees as defined in the
Retirement Plan. The Board of Directors of Par authorized the cessation of
employer contributions effective December 30, 1996. Consequently, participants
in the Retirement Plan will no longer be entitled to any employer contributions
under such plan for 1996 or subsequent years. The Company also maintains a
Retirement Savings Plan whereby eligible employees are permitted to contribute
from 1% to 12% of pay to this Plan. The Company contributes an amount equal to
50% of the first 6% of the pay contributed by the employee. In fiscal 1998, the
Company intends to merge the Retirement Plan into the Retirement Savings Plan.
Legal Proceedings:
The Company is involved in certain litigation matters, including certain
product liability actions and actions by two former officers for, among other
things, breach of contract. Such actions seek damages from the Company,
including compensatory and punitive damages. The Company intends to defend
these actions vigorously. The Company believes that these actions are
incidental to the conduct of its business and that the ultimate resolution
thereof will not have a material adverse effect on its financial condition or
results of operations.
Restructuring and Cost Reductions:
The Company implemented measures beginning in the fourth quarter of fiscal
1996, which continued throughout fiscal 1997, to reduce costs and increase
operating efficiencies. Such measures have provided for a reduction of the work
force, changes in various senior management, a reorganization of certain
existing personnel and reductions in certain expenses.
Other Matters:
The Company loaned to another generic drug manufacturer $500,000 through
December 27, 1997 for working capital purposes. The loan, payable on February
27, 1998, bears interest at a rate of 10% per annum and is secured by certain
assets of the generic drug manufacturer. In addition, through the date of this
Form 10-Q, the Company provided the generic drug manufacturer an additional loan
of $350,000. The Company and the generic drug manufacturer are discussing the
terms of a distribution agreement. There can be no assurance that the Company
will be successful in signing such an agreement or that the loan will be repaid
in whole or in part.
--7--
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
CERTAIN STATEMENTS IN THIS FORM 10-Q CONSTITUTE "FORWARD-LOOKING STATEMENTS"
WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995,
INCLUDING THOSE CONCERNING MANAGEMENT'S EXPECTATIONS WITH RESPECT TO FUTURE
FINANCIAL PERFORMANCE AND FUTURE EVENTS, PARTICULARLY RELATING TO SALES OF
CURRENT PRODUCTS AS WELL AS THE INTRODUCTION OF NEW MANUFACTURED AND DISTRIBUTED
PRODUCTS. SUCH STATEMENTS INVOLVE KNOWN AND UNKNOWN RISKS, UNCERTAINTIES AND
CONTINGENCIES, MANY OF WHICH ARE BEYOND THE CONTROL OF THE COMPANY, WHICH COULD
CAUSE ACTUAL RESULTS AND OUTCOMES TO DIFFER MATERIALLY FROM THOSE EXPRESSED
HEREIN. FACTORS THAT MIGHT AFFECT SUCH FORWARD-LOOKING STATEMENTS SET FORTH IN
THIS FORM 10-Q INCLUDE, AMONG OTHERS, (I) INCREASED COMPETITION FROM NEW AND
EXISTING COMPETITORS AND PRICING PRACTICES FROM SUCH COMPETITORS, (II) PRICING
PRESSURES RESULTING FROM THE CONTINUED CONSOLIDATION BY THE COMPANY'S
DISTRIBUTION CHANNELS, (III) THE AMOUNT OF FUNDS CONTINUING TO BE AVAILABLE FOR
INTERNAL RESEARCH AND DEVELOPMENT AND RESEARCH AND DEVELOPMENT JOINT VENTURES,
(IV) RESEARCH AND DEVELOPMENT PROJECT DELAYS OR DELAYS IN OBTAINING REGULATORY
APPROVALS, (V) THE ABILITY OF THE COMPANY TO RETAIN AND ATTRACT MANAGEMENT
PERSONNEL IN KEY OPERATIONAL AREAS AND (VI) CONTINUED AVAILABILITY OF BORROWINGS
UNDER THE COMPANY'S CREDIT LINE WITHOUT SIGNIFICANT REDUCTION.
RESULTS OF OPERATIONS
GENERAL
The Company's operating loss was $1,992,000 for the three-month period ended
December 27, 1997 compared to an operating loss of $2,596,000 for the three-
month period ended December 28, 1996. The improvement of $604,000 was
principally due to increased gross margins and lower selling, general and
administrative expenses, as described below. If current sales and gross margin
levels are not increased from sales of new distributed or manufactured products,
the Company will continue to experience losses. As a result of the continuing
losses, the Company is searching for strategic alternatives to strengthen its
financial condition and product line while working on process improvements to
reduce its current manufacturing costs.
The continued price and profit margin erosion on certain of the Company's
products reflects the continuing trend in the generic drug industry in the
United States. The factors contributing to the intense competition and
affecting both the introduction of new products and the pricing and profit
margins of the Company, include, among other things, (i) introduction of other
generic drug manufacturer's products in direct competition with the Company's
significant products, (ii) consolidation among distribution outlets, (iii)
increased ability of generic competitors to enter the market after patent
expiration, diminishing the amount and duration of significant profits, (iv)
willingness of generic drug customers, including wholesale and retail customers,
to switch among pharmaceutical manufacturers, and (v) competition from brand
name drug manufacturers selling generic versions of their drugs. In response to
these conditions, the Company has reduced operating costs and entered into
several significant agreements, as described elsewhere in this Form 10-Q, which
should enable the Company to better compete in the current environment (see
"Notes to Financial Statements-Distribution Agreements" and "-Commitments,
Contingencies and Other Matters-Restructuring and Cost Reductions").
Critical to significant improvement in the Company's financial condition is
the introduction and acquisition of new manufactured and distributed products at
profitable prices. The Company plans to continue to invest in research and
development efforts in addition to pursuing additional products for sale through
new and existing distribution agreements. The Company is engaged in efforts,
subject to FDA approval and other factors, to introduce new products as a result
of its research and development efforts and distribution agreements. No
assurance can be given that any additional products for sale by the Company will
occur or that sales of additional products will reduce losses or return the
Company to profitability. Continuing losses will adversely affect the Company's
liquidity and, accordingly, its ability to fund research and development or
ventures relating to the sale of new products (see "-Financial Condition-
Liquidity and Capital Resources").
--8--
NET SALES
Net sales for the three months ended December 27, 1997 of $12,134,000
decreased $336,000, or 3%, from sales of $12,470,000 for the corresponding
period of the prior fiscal year. Manufactured products continued to experience
decreased sales which resulted primarily from lower pricing and continuing
decreases in volume of one of the Company's significant products, and to a
lesser extent, two other significant products, partially offset by higher
volumes of a lower margin product due to increased demand from two customers.
The reductions in pricing and volume resulted from increased competition from
other drug manufacturers. Net sales in the current fiscal quarter of two
distributed products manufactured by BASF under the Supply Agreement experienced
significant increases over the same period of the prior year helping to offset
the decline in sales of certain manufactured products.
Levels of sales are principally dependent upon, among other things, (i)
pricing levels and competition, (ii) market penetration for the existing product
line, (iii) approval of ANDAs and introduction of new manufactured products,
(iv) introduction of new distributed products, and (v) the level of customer
service.
GROSS MARGIN
The Company's gross margin of $1,504,000 (12% of net sales) for the three
months ended December 27, 1997 increased by $272,000 from $1,232,000 (10% of net
sales) in the corresponding period of the prior fiscal year. The gross margin
improvement is due to increased contributions from products manufactured by BASF
under the Supply Agreement, higher volumes of a lower margin manufactured
product together with more favorable raw material pricing, and decreased
manufacturing costs. These improvements more than offset the lower selling
prices and decreased volumes of certain significant manufactured products
resulting from the introduction of other generic drug manufacturers' products in
direct competition with the Company's significant products.
Inventory write-offs, taken in the normal course of business, amounted to
$293,000 for the three-month period ended December 27, 1997, reflecting an
improvement over $333,000 in the corresponding period of the prior year. The
inventory write-offs are related principally to the disposal of finished
products due to short shelf life.
OPERATING EXPENSES
Research and Development
Research and development expenses for the three-month period ended December
27, 1997 increased by $204,000 from the three-month period ended December 28,
1996. In August 1997, the Company acquired Clal's 51% ownership interest in IPR
in which PRI previously had owned 49% (see "Notes to Financial Statements-
Acquisition of Joint Venture"). The Company recorded an aggregate of $442,000
in research and development expenses for IPR in the current quarter compared to
$148,000 in the same quarter of the prior year. The higher costs of IPR were
partially offset by lower domestic spending on research and development.
During fiscal year 1997, the Company's domestic research and development
program was fully integrated with the research operations in Israel. The
Company has ANDAs for four potential products pending with the FDA and awaiting
approval and expects to complete an additional submission for a product in the
second quarter of fiscal 1998.
The Company has a distribution agreement with Sano to distribute generic
transdermal products developed by Sano. Sano has ANDAs for two potential
products, which are covered by the distribution agreement, filed with the FDA
and awaiting approval. The Company began selling the nicotine patch
manufactured by Sano in January 1998 (see "Notes to Financial Statements-
Distribution Agreements").
--9--
Selling, General and Administrative
Selling, general and administrative costs for the three-month period ended
December 27, 1997 of $2,588,000 (21% of net sales) were reduced $536,000, or
17%, from $3,124,000 (25% of net sales) for the corresponding period in the
prior fiscal year. The decrease in the period is primarily attributable to a
decline in personnel costs resulting from head count reductions (see "Notes to
Financial Statements-Restructuring and Cost Reductions").
INCOME TAXES
Management has determined, based on the Company's recent performance and
the uncertainty of the generic business in which the Company operates, that
future operating income might not be sufficient to recognize fully the net
operating loss carryforwards of the Company. Therefore, the Company did not
recognize a benefit for its operating losses in either of the three-month
periods ended December 27, 1997 or December 28, 1996 (see "Notes to Financial
Statements-Income Taxes"). The Company incurred income tax expense of $410,000
in the first quarter of fiscal year 1997 due to interest relating to a
settlement with the Internal Revenue Service in fiscal year 1995 for the
disallowance of the Company's tax credit for prior periods with respect to
certain research and development credits.
FINANCIAL CONDITION
LIQUIDITY AND CAPITAL RESOURCES
Working capital decreased $2,350,000 to $13,609,000 at December 27, 1997
from $15,959,000 at September 30, 1997. The decrease is principally due to the
use of funds to finance operating losses. As a result of a cash management
system pursuant to the financing agreement that the Company entered into with
GECC, the only remaining cash balance at December 27, 1997 was cash at IPR (see
"--Financing"). The working capital ratio of 2.0x in the current period
declined from 2.3x at fiscal 1997 year end.
The Company loaned to another generic drug manufacturer $500,000 through
December 27, 1997 for working capital purposes. The loan, payable on February
27, 1998, bears interest at a rate of 10% per annum and is secured by certain
assets of the generic drug manufacturer. In addition, through the date of this
Form 10-Q, the Company provided the generic drug manufacturer an additional loan
of $350,000. The Company and the generic drug manufacturer are discussing the
terms of a distribution agreement. There can be no assurance that the Company
will be successful in signing such an agreement or that the loan will be repaid
in whole or in part (see "Notes to Financial Statements-Commitments,
Contingencies and Other Matters-Other Matters").
In August 1997, the Company, through one of its subsidiaries, acquired
Clal's 51% ownership interest in their research and development joint venture in
Israel for $447,000 in cash obtained from the sale of Fine-Tech stock and a non-
recourse secured promissory note for $1,500,000 bearing interest at 7%. The
Company has the option to prepay the note for $600,000 by August 12, 1998. The
Company is obligated to invest not less than $1,500,000 each year in IPR until
the note is repaid (see "Notes to Financial Statements-Acquisition of Joint
Venture").
In return for relinquishing certain rights pursuant to the amendment of the
Company's distribution agreement with Sano, PRI received $1,950,000 in cash in
the fourth quarter of fiscal year 1997, which was used to reduce the revolving
credit line balance, and an interest bearing promissory note for $1,950,000
which will be due in September 1998 (see "Notes to Financial Statements-
Distribution Agreement").
The Company expects to fund its operations, including research and
development activities and its obligations under the existing distribution and
development arrangements discussed above, out of its working capital, and if
necessary with borrowings against its line of credit, to the extent then
available (see "--Financing"). If, however, the Company continues to experience
significant losses, its liquidity and, accordingly, its ability to fund research
and development or ventures relating to the distribution of new products will be
materially and adversely affected.
--10--
FINANCING
At December 27, 1997, the Company's total outstanding short-term and long-
term debt amounted to $6,915,000 and $2,807,000, respectively. The short-term
debt consists of the outstanding amount under the Company's line of credit with
GECC and the long-term debt consists primarily of an outstanding mortgage loan
with a bank and a non-recourse secured promissory note resulting from the
acquisition of Clal's interest in IPR in fiscal year 1997.
In December 1996, Par entered into the Loan Agreement with GECC which
provided Par with a three-year revolving line of credit. Pursuant to the Loan
Agreement, as amended, Par is permitted to borrow up to the lesser of (i) the
borrowing base established under the Loan Agreement or (ii) $20,000,000. The
borrowing base is limited to 85% of eligible accounts receivable plus 50% of
eligible inventory of Par, each as determined from time to time by GECC. The
interest rate charge on the line of credit is based upon a per annum rate of
3.50% above the 30-day commercial paper rate for high-grade unsecured notes
adjusted monthly. The line of credit with GECC is secured by the assets of Par
and PRI other than real property and is guaranteed by PRI. In connection with
such facility, Par, PRI and their affiliates have established a cash management
system pursuant to which all cash and cash equivalents received by any of such
entities are deposited into a lockbox account over which GECC has sole operating
control and which are applied on a daily basis to reduce amounts outstanding
under the line of credit. The revolving credit facility is subject to covenants
based on various financial benchmarks. In fiscal year 1997, GECC waived events
of default on three occasions unrelated to the repayment of debt under the Loan
Agreement. As of December 27, 1997, the borrowing base was approximately
$8,600,000 and $6,915,000 was outstanding under the line of credit. Any
significant reduction in the borrowing base from its current levels will
adversely affect the Company's liquidity.
--11--
PART II. OTHER INFORMATION
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K.
- ------ --------------------------------
(a) Exhibits:
27 - Financial Data Schedule.
(b) Reports on Form 8-K:
None.
--12--
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
PHARMACEUTICAL RESOURCES, INC.
------------------------------
(Registrant)
February 10, 1998 /s/ Kenneth I. Sawyer
------------------------------
Kenneth I. Sawyer
President and Chief Executive Officer
(Principal Executive Officer)
February 10, 1998 /s/ Dennis J. O'Connor
------------------------------
Dennis J. O'Connor
Vice President - Chief Financial Officer and
Secretary
(Principal Accounting and Financial Officer)
--13--
EXHIBIT INDEX
-------------
Exhibit Number Description Page Number
- ---------------- ----------------------- -----------
27 Financial Data Schedule 15
--14--